Limits...
Oral Bromelain Attenuates Inflammation in an Ovalbumin-induced Murine Model of Asthma.

Secor ER, Carson WF, Singh A, Pensa M, Guernsey LA, Schramm CM, Thrall RS - Evid Based Complement Alternat Med (2008)

Bottom Line: Bromelain, a widely used pineapple extract with cysteine protease activity, has been shown to have immunomodulatory effects in a variety of immune system models.Oral bromelain-treatment of AAD mice demonstrated therapeutic efficacy as evidenced by decreased methacholine sensitivity (P </= 0.01), reduction in BAL eosinophils (P </= 0.02) and IL-13 concentrations (P </= 0.04) as compared with PBS controls.These results suggest that oral treatment with bromelain had a beneficial therapeutic effect in this murine model of asthma and bromelain may also be effective in human conditions.

View Article: PubMed Central - PubMed

Affiliation: Department of Immunology and Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT, USA.

ABSTRACT
Bromelain, a widely used pineapple extract with cysteine protease activity, has been shown to have immunomodulatory effects in a variety of immune system models. The purpose of the present study was to determine the effects of orally administered bromelain in an ovalbumin (OVA)-induced murine model of acute allergic airway disease (AAD). To establish AAD, female C57BL/6J mice were sensitized with intraperitoneal (i.p.) OVA/alum and then challenged with OVA aerosols for 3 days. Mice were gavaged with either (phosphate buffered saline)PBS or 200 mg/kg bromelain in PBS, twice daily for four consecutive days, beginning 1 day prior to OVA aerosol challenge. Airway reactivity and methacholine sensitivity, bronchoalveolar lavage (BAL) cellular differential, Th2 cytokines IL-5 and IL-13, and lung histology were compared between treatment groups. Oral bromelain-treatment of AAD mice demonstrated therapeutic efficacy as evidenced by decreased methacholine sensitivity (P

No MeSH data available.


Related in: MedlinePlus

The effect of oral Bromelain treatment on lung pathology. Top panels: No evidence of histological injury was noted in naïve animals (A) or oral Bromelain treated naïve animals (B). Lower panels: As previously described, 3 day AAD mice develop pathological changes characterized by perivascular and peribronchiolar infiltration of lymphocytes, eosinophils and plasma cells (C), which was reduced in oral Bromelain treated AAD mice (D).
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC2249734&req=5

Figure 6: The effect of oral Bromelain treatment on lung pathology. Top panels: No evidence of histological injury was noted in naïve animals (A) or oral Bromelain treated naïve animals (B). Lower panels: As previously described, 3 day AAD mice develop pathological changes characterized by perivascular and peribronchiolar infiltration of lymphocytes, eosinophils and plasma cells (C), which was reduced in oral Bromelain treated AAD mice (D).

Mentions: Histological evaluations and Pathology Scores (PS), were performed on unmanipulated, uninflated formalin-fixed lungs from separate groups (n = 4) of naïve, naïve bromelain-treated, AAD saline- and AAD bromelain-treated mice stained with hematoxylin and eosin (H & E), Mallory's trichrome and periodic acid-schiff. The H & E stain has been included for comparison (Fig. 6). As demonstrated in the top panels, no evidence of histological injury was noted in naïve animals (A) or oral bromelain-treated naïve animals (B). Three day AAD mice develop mild pathologic changes, characterized by perivascular and peribronchial (arrows) inflammation which includes cellular infiltrates (lymphocytes, plasma cells and eosinophils). These changes are present in the 3-day AAD saline-treated mice (C). Oral bromelain-treated AAD mice (D) appeared to have minimal histological injury. However, upon statistical comparisons of pathological scoring by four reviewers, there were no statistical changes in pathological scoring.Figure 6.


Oral Bromelain Attenuates Inflammation in an Ovalbumin-induced Murine Model of Asthma.

Secor ER, Carson WF, Singh A, Pensa M, Guernsey LA, Schramm CM, Thrall RS - Evid Based Complement Alternat Med (2008)

The effect of oral Bromelain treatment on lung pathology. Top panels: No evidence of histological injury was noted in naïve animals (A) or oral Bromelain treated naïve animals (B). Lower panels: As previously described, 3 day AAD mice develop pathological changes characterized by perivascular and peribronchiolar infiltration of lymphocytes, eosinophils and plasma cells (C), which was reduced in oral Bromelain treated AAD mice (D).
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC2249734&req=5

Figure 6: The effect of oral Bromelain treatment on lung pathology. Top panels: No evidence of histological injury was noted in naïve animals (A) or oral Bromelain treated naïve animals (B). Lower panels: As previously described, 3 day AAD mice develop pathological changes characterized by perivascular and peribronchiolar infiltration of lymphocytes, eosinophils and plasma cells (C), which was reduced in oral Bromelain treated AAD mice (D).
Mentions: Histological evaluations and Pathology Scores (PS), were performed on unmanipulated, uninflated formalin-fixed lungs from separate groups (n = 4) of naïve, naïve bromelain-treated, AAD saline- and AAD bromelain-treated mice stained with hematoxylin and eosin (H & E), Mallory's trichrome and periodic acid-schiff. The H & E stain has been included for comparison (Fig. 6). As demonstrated in the top panels, no evidence of histological injury was noted in naïve animals (A) or oral bromelain-treated naïve animals (B). Three day AAD mice develop mild pathologic changes, characterized by perivascular and peribronchial (arrows) inflammation which includes cellular infiltrates (lymphocytes, plasma cells and eosinophils). These changes are present in the 3-day AAD saline-treated mice (C). Oral bromelain-treated AAD mice (D) appeared to have minimal histological injury. However, upon statistical comparisons of pathological scoring by four reviewers, there were no statistical changes in pathological scoring.Figure 6.

Bottom Line: Bromelain, a widely used pineapple extract with cysteine protease activity, has been shown to have immunomodulatory effects in a variety of immune system models.Oral bromelain-treatment of AAD mice demonstrated therapeutic efficacy as evidenced by decreased methacholine sensitivity (P </= 0.01), reduction in BAL eosinophils (P </= 0.02) and IL-13 concentrations (P </= 0.04) as compared with PBS controls.These results suggest that oral treatment with bromelain had a beneficial therapeutic effect in this murine model of asthma and bromelain may also be effective in human conditions.

View Article: PubMed Central - PubMed

Affiliation: Department of Immunology and Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT, USA.

ABSTRACT
Bromelain, a widely used pineapple extract with cysteine protease activity, has been shown to have immunomodulatory effects in a variety of immune system models. The purpose of the present study was to determine the effects of orally administered bromelain in an ovalbumin (OVA)-induced murine model of acute allergic airway disease (AAD). To establish AAD, female C57BL/6J mice were sensitized with intraperitoneal (i.p.) OVA/alum and then challenged with OVA aerosols for 3 days. Mice were gavaged with either (phosphate buffered saline)PBS or 200 mg/kg bromelain in PBS, twice daily for four consecutive days, beginning 1 day prior to OVA aerosol challenge. Airway reactivity and methacholine sensitivity, bronchoalveolar lavage (BAL) cellular differential, Th2 cytokines IL-5 and IL-13, and lung histology were compared between treatment groups. Oral bromelain-treatment of AAD mice demonstrated therapeutic efficacy as evidenced by decreased methacholine sensitivity (P

No MeSH data available.


Related in: MedlinePlus